| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16632
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0331
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16651
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16643
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16621 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-763
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-763
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 |
| filingDate |
2018-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2021-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102227180-B1 |
| titleOfInvention |
Recombinant herpes simplex virus and uses thereof |
| abstract |
The present invention relates to virology and tumor treatment. In particular, the present invention provides a recombinant herpes simplex virus (HSV) capable of effectively killing tumor cells by replicating specifically at a high level in tumor cells, but replicating at a low level in normal cells. Not only the apoptosis rate of the recombinant herpes simplex tumor cells of the present invention is high, but also side effects (especially neurotoxicity) are significantly reduced. In addition, the present invention relates to the use of a viral vector constructed based on a recombinant herpes simplex virus, a recombinant herpes simplex virus or a pharmaceutical composition comprising a viral vector, a recombinant herpes simplex virus or a viral vector. The recombinant herpes simplex virus of the present invention can be used to infect and kill tumor cells, and can be used to deliver gene drugs to tumor cells for gene therapy. |
| priorityDate |
2017-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |